Alector Investor
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Investors
Technology:
Gene therapy
Industry:
Biotechnology, Health Care, Science and Engineering
Headquarters:
United States
Founded Date:
2013-01-01
Employees Number:
101-250
Funding Status:
IPO
Number Of Exits:
1
Investors Number:
19
Total Funding:
194500000 USD
Estimated Revenue:
$10M to $50M
Last Funding Date:
2018-07-25
Last Funding Type:
Series E
Register and Claim Ownership